Clinical Data ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH Pharmaceutical TechnologyNew data presented at ACC 2026 clarifies sotatercept's role alongside vasodilator-based regimens in PAH patients.Clinical DataCardiovascularRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaceutical Technology New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients. Clinical DataCardiovascularRead full story Post navigation Previous: Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is ChillingNext: Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026